RATIO-SALBUTAMOL SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

SALBUTAMOL (SALBUTAMOL SULFATE)

متاح من:

TEVA CANADA LIMITED

ATC رمز:

R03AC02

INN (الاسم الدولي):

SALBUTAMOL

جرعة:

2MG

الشكل الصيدلاني:

SOLUTION

تركيب:

SALBUTAMOL (SALBUTAMOL SULFATE) 2MG

طريقة التعاطي:

INHALATION

الوحدات في الحزمة:

2.5ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0108887001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2018-06-22

خصائص المنتج

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate nebules P.F. 1.25MG/2.5 ML, 5.0 MG/2.5 ML AMPOULES
Bronchodilator
(beta
2
-adrenergic stimulant)
TEVA CANADA LIMITED..
30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA, M1B 2K9
Control: 165512
DATE OF PREPARATION:
JULY 3, 2013
Teva Canada Limited.
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
7
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................